Novartis' Tafinlar/Mekinist combo scores new indication in pediatric brain cancer
Novartis’ Tafinlar (dabrafenib) and Mekinist (trametinib) combo has been approved for another indication by the FDA — this time for treatment of low-grade glioma with a BRAF V600E mutation in kids aged 1 year and up.
This marks the sixth approval for the combination. It’s already approved for use in multiple BRAF V600E solid tumors, including melanoma, thyroid cancer and lung cancer.
Liquid formulations for both drugs were also approved by the FDA, which Novartis said is the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.